Ceapro Inc V.CZO

Chemicals Specialty Chemicals

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

TSXV:CZO - Post by User

Ceapro Inc > Failure, again.

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Nov 29, 2023 1:18pm

64 Views

Post# 35759011

RE:Failure, again.

"The language about a solid base business and slow ordering is gone so we can assume ten million is the new revenue run rate. Gilles had one thing and that was the reliable base business that he always claimed to have built, well that's gone."

Just last month Gilles said at the presentation that he is confident 2024 will return to historical trends once the adjustment in 2023 have been completed. CZO is the only supplier of the product Kenvue requires.

6:00 Ceapro (TSX.V: CZO) CEO Gilles Gagnon – Small Cap Discoveries

CZO is also launching powder formulations has new potential claims for wound healing, and he expected the oat powder beta glucan to be launched "very, very soon". There is the avenanthramide malted technology. The 10X scale-up of PGX will also allow commercial sales.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China